Faculty Opinions recommendation of Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727471255.793549067 ◽

2018 ◽

Author(s):

Eduard Stange ◽

Jan Wehkamp

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Intestinal Inflammation ◽

Oncostatin M ◽

Inflammatory Bowel ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727471255.793531335 ◽

2017 ◽

Author(s):

Sanjiv Luther

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Intestinal Inflammation ◽

Oncostatin M ◽

Inflammatory Bowel ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727471255.793531087 ◽

2017 ◽

Author(s):

Lars Rogge

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Intestinal Inflammation ◽

Oncostatin M ◽

Inflammatory Bowel ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727471255.793569700 ◽

2020 ◽

Author(s):

Jack Satsangi

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Intestinal Inflammation ◽

Oncostatin M ◽

Inflammatory Bowel ◽

Necrosis Factor

Download Full-text

Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease

10.1055/s-0037-1604794 ◽

2017 ◽

Author(s):

AN Hegazy ◽

N West ◽

B Owens ◽

S Bullers ◽

B Linggi ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Intestinal Inflammation ◽

Oncostatin M ◽

Inflammatory Bowel ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727471255.793537836 ◽

2017 ◽

Author(s):

Gwo-Tzer Ho

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Intestinal Inflammation ◽

Oncostatin M ◽

Inflammatory Bowel ◽

Necrosis Factor

Download Full-text

Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease

Nature Medicine ◽

10.1038/nm0617-788d ◽

2017 ◽

Vol 23 (6) ◽

pp. 788-788 ◽

Author(s):

Nathaniel R West ◽

◽

Ahmed N Hegazy ◽

Benjamin M J Owens ◽

Samuel J Bullers ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Intestinal Inflammation ◽

Oncostatin M ◽

Inflammatory Bowel ◽

Necrosis Factor

Download Full-text

Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease

Nature Medicine ◽

10.1038/nm.4307 ◽

2017 ◽

Vol 23 (5) ◽

pp. 579-589 ◽

Author(s):

Nathaniel R West ◽

◽

Ahmed N Hegazy ◽

Benjamin M J Owens ◽

Samuel J Bullers ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Intestinal Inflammation ◽

Oncostatin M ◽

Inflammatory Bowel ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.728770716.793568133 ◽

2019 ◽

Author(s):

Ashish Patel

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Therapeutic Drug Monitoring ◽

Bowel Disease ◽

Drug Monitoring ◽

Tumor Necrosis ◽

Therapeutic Drug ◽

Factor Therapy ◽

Inflammatory Bowel ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732092122.793568144 ◽

2019 ◽

Author(s):

Ashish Patel

Keyword(s):

Inflammatory Bowel Disease ◽

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Antagonists ◽

Inflammatory Bowel ◽

Necrosis Factor

Download Full-text

Anti Tumor Necrosis Factor-a Monoclonal Antibody (Infliximab) Therapy in Patients with Inflammatory Bowel Disease (IBD): Applications and Side Effects

Drug Design Reviews - Online ◽

10.2174/1567269043480645 ◽

2004 ◽

Vol 1 (2) ◽

pp. 111-117 ◽

Author(s):

L. Amati ◽

M. Passeri ◽

M. Mastronardi ◽

E. Jirillo

Keyword(s):

Inflammatory Bowel Disease ◽

Monoclonal Antibody ◽

Side Effects ◽

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Infliximab Therapy ◽

Inflammatory Bowel ◽

Necrosis Factor

Download Full-text